Hospira revenue rises 14 percent on higher sales of injectable drugs

(Reuters) – Drugmaker Hospira Inc reported a 14.1 percent rise in quarterly revenue as it charged higher prices and sold more of its injectable drugs. The company’s net income rose to $158.6 million, or 92 cents per share, in the quarter ended Sept. 30 from $1.9 million, or 1 cent per share, a year earlier. The increase was mainly due to a $106.3 million gain on the sale of its clinical surveillance software business, Theradoc. Revenue rose to $1.2 billion from $1 billion. Sales of injectable drugs rose 16.7 percent and accounted for about 55 percent of total sales. …
Go to Source